Table 2.
Body composition parameters and profiles pre- and post-neoadjuvant therapy. Continuous variables were presented as means ± standard deviations (SD, normally distributed variables) or medians ± interquartile ranges (IQR, non-normally distributed variables). Continuous parameters pre- and post-neoadjuvant therapy were compared by paired T test or Wilcoxon matched-pairs signed rank test based on normality testing. Group comparisons involving dichotomous or categorical variables were performed using the chi-square test or Fisher’s exact test as appropriate
| Pre-neoadjuvant therapy | Post-neoadjuvant therapy | P | |
|---|---|---|---|
| SMI, mean (SD) | 50.9 (8.2) | 50.8 (8.0) | ns |
| VFA, mean (SD) | 179.9 (115.5) | 177.7 (104.5) | ns |
| SFA, median (IQR) | 163.6 (34.7) | 163.0 (23.3) | ns |
| VFA/SFA ratio, median (IQR) | 0.90 (0.42) | 0.84 (0.26) | ns |
| PFA, median (IQR) | 12.4 (4.5) | 11.8 (3.9) | ns |
| BMI, mean (SD) | 27.1 (4.3) | 27.0 (3.5) | ns |
|
Sarcopenia Yes, % (n) No, % (n) |
36.8 (28) 63.2 (48) |
36.8 (28) 63.2 (48) |
ns |
|
Sarcopenic obesity Yes, % (n) No, % (n) |
4.8 (3) 95.2 (60) |
9.2 (7) 90.8 (69) |
ns |
|
Visceral obesity Yes, % (n) No, % (n) |
63.6 (49) 36.4 (28) |
64.5 (49) 35.5 (27) |
ns |
|
Perinephric obesity Yes, % (n) No, % (n) |
35.1 (27) 64.9 (50) |
37.7 (29) 62.3 (50) |
ns |
|
BMI obesity Yes, % (n) No, % (n) |
26.3 (15) 73.7 (42) |
19.5 (15) 80.5 (62) |
ns |